Published in Medical Letter on the CDC and FDA, June 20th, 2004
Dr. Puthupparampil Scaria, vice president of synthetic vectors at Intradigm, is the principle investigator of this grant, titled "Targeted delivery of siRNA to inhibit tumor growth." This lead product conveys two levels of targeting - tissue-targeted siRNA that inhibits the VEGF pathway selectively at new blood vessels within tumors.
The VEGF pathway is a key for the process used by tumors to generate the new blood vessels they...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.